Medicare's CBD pilot is live — here's what the $500 benefit actually covers, and who's trying to stop it
The CMS Innovation Center launched its Substance Access Beneficiary Engagement Incentive on April 1, allowing select Medicare patients to receive up to $500 in physician-supervised, hemp-derived CBD products annually. But an April 20 court date could shut it down before it scales.
The Centers for Medicare & Medicaid Services launched a first-of-its-kind program on April 1, 2026, creating a structured federal pathway for Medicare patients to access physician-supervised, hemp-derived CBD products. The program marks the first time the U.S. government has built a framework connecting Medicare beneficiaries to cannabinoid products under medical oversight.
What the program is
Formally called the Substance Access Beneficiary Engagement Incentive (BEI), the program operates under CMS's Innovation Center. It is currently available through two existing Medicare models — ACO REACH and the Enhancing Oncology Model — with the LEAD Model scheduled to join on January 1, 2027.
The benefit caps at $500 per eligible beneficiary per year. Five Accountable Care Organizations participating in ACO REACH have submitted implementation plans to CMS.
Charlotte's Web Holdings and NuLeaf Naturals, a subsidiary of High Tide Inc., have been announced as approved suppliers for participating organizations.
What it covers — and what it doesn't
The program comes with strict product requirements:
- Oral formulations only — no inhalable products of any kind
- Maximum 0.3% delta-9 THC by dry weight
- Maximum 3mg total THC per serving
- Products must be furnished directly by a physician affiliated with the participating organization
A critical distinction: Medicare does not directly pay for the CBD products. Participating organizations bear the cost themselves. CMS frames the entire effort as a data-collection initiative — gathering real-world clinical evidence on hemp-derived CBD outcomes among Medicare beneficiaries.
The FDA's unusual posture
On April 1, FDA Commissioner Dr. Marty Makary issued a letter easing the agency's enforcement posture for CBD products eligible under the CMS pilot. The move was notable given the FDA's historically cautious stance on cannabinoid products.
However, the letter introduced a policy tension that legal observers quickly flagged. The FDA referenced a 0.4mg THC per container threshold drawn from the agency's upcoming hemp product regulations, while CMS allows up to 3mg per serving under the pilot. How these two frameworks will coexist remains an open question.
The legal challenge
Smart Approaches to Marijuana (SAM), a prominent anti-legalization advocacy group, filed a lawsuit on March 30 to block the program. The suit names CMS Administrator Dr. Mehmet Oz and Health Secretary Robert F. Kennedy Jr. as defendants.
SAM sought an emergency temporary restraining order to prevent the April 1 launch. A federal judge denied the request, allowing the program to go live as scheduled.
A hearing on a preliminary injunction — which could suspend the program while litigation continues — is scheduled for April 20. The irony of the date has not been lost on observers.
How we got here
The CMS pilot didn't emerge in a vacuum. It sits at the end of a long chain of federal actions on cannabis policy:
- October 2022 — President Biden orders a federal review of marijuana scheduling
- August 2023 — HHS recommends reclassifying marijuana to Schedule III
- May 2024 — DEA publishes a proposed rescheduling rule
- August 2024 — More than 42,000 public comments are submitted on the proposed rule
- December 2025 — President Trump signs an executive order directing expedited rescheduling
- March 2026 — CMS announces the Beneficiary Engagement Incentive
- March 30, 2026 — SAM files lawsuit to block the program
- April 1, 2026 — Program launches; FDA eases enforcement posture
- April 20, 2026 — Court hearing on preliminary injunction
The bottom line
Whatever happens in court on April 20, the BEI represents a policy milestone: the federal government has, for the first time, created a structured mechanism for Medicare patients to access cannabinoid products under physician supervision. Whether it survives legal challenge — and whether the clinical data it generates proves meaningful — will shape the next chapter of federal cannabis policy.